The mitogen-activated protein kinase (MAPK) pathway regulates growth and survival of many cell types, and its constitutive activation has been implicated in the pathogenesis of a variety of malignancies. In this study we demonstrate that small-molecule MEK inhibitors (PD98059 and PD184352) profoundly impair cell growth and survival of acute myeloid leukemia (AML) cell lines and primary samples with constitutive MAPK activation. These agents abrogate the clonogenicity of leukemic cells but have minimal effects on normal hematopoietic progenitors. MEK blockade also results in sensitization to spontaneous and drug-induced apoptosis. At a molecular level, these effects correlate with modulation of the expression of cyclin-dependent kinase inhibitors (p27 Kip1 and p21 Waf1/CIP1 ) and antiapoptotic proteins of the inhibitor of apoptosis proteins (IAP) and Bcl-2 families. Interruption of constitutive MEK/MAPK signaling therefore represents a promising therapeutic strategy in AML.
cells were purified by Ficoll-Hypaque (Sigma Chemical Co., St. Louis, Missouri, USA) density-gradient centrifugation. CD34 + cells were separated to greater than 95% purity by positive-selection magnetic-bead sorting using a VarioMACS device (Miltenyi Biotec, Auburn, California, USA). Cell lines were harvested in log-phase growth and exposed to the MEK inhibitors PD98059 (2′-amino-3′-methoxyflavone; Calbiochem-Novabiochem Corp., La Jolla, California, USA) (15, 16) and PD184352 (2-[2-chloro-4-iodo-phenylamino]-N-cyclopropylmethoxy-3,4-difluoro-benzamide) (17) , or to a matched concentration of vehicle (DMSO). In combination experiments, cells were preincubated with PD98059 for 1 hour prior to the addition of all-trans-retinoic acid (ATRA). In other experiments, cells were seeded at 5 × 10 5 cells/ml and exposed to 1-β-D-arabinofuranosylcytosine (Ara-C) for 4 hours at 37°C. Ara-C was then removed and cells were plated at 1 × 10 5 cells/ml in the presence of either DMSO or PD98059. In all experiments, cell viability was evaluated by triplicate counting of trypan blue dye-excluding cells under a light microscope. AML blast and normal bone marrow progenitor colony assays were performed as previously described (18) .
Cell cycle and apoptosis analysis. Cells were fixed in icecold ethanol (70% vol/vol) and stained with propidium iodide (PI) solution (25 µg/ml PI, 180 U/ml RNase, 0.1% Triton X-100, and 30 mg/ml polyethylene glycol in 4 mM citrate buffer, pH 7.8; Sigma Chemical Co.). The DNA content was determined using a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, California, USA). Cell cycle distribution was analyzed using ModFit LT software (Verity Software House Inc., Topsham, Maine, USA). Cells with a hypodiploid DNA content (< 2n, > 0.2n) were counted as apoptotic. For annexin V binding studies, cells were washed twice with binding buffer (10 mM HEPES, 140 mM NaCl, and 5 mM CaCl 2 at pH 7.4; Sigma Chemical Co.) and incubated with a 1:500 solution of FITC-conjugated annexin V (Roche Diagnostic Corp., Indianapolis, Indiana, USA) for 15 minutes at room temperature. Stained cells were analyzed by flow cytometry, while membrane integrity was simultaneously assessed by PI exclusion.
Western blot analysis and in vitro kinase assay. For phosphorylation studies, cells were lysed for 10 minutes on ice in a solution containing 10 mM NaF, 1 mM Na 3 VO 4 , 150 mM NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 0.1% NaN 3 , 10 mM iodoacetamide, 3 mM PMSF, and 1% Triton X-100, supplemented with a protease inhibitor cocktail (Roche Diagnostic Corp.). Equal amounts of proteins were subjected to SDS-PAGE, transferred to Hybond-P membranes (Amersham Pharmacia Biotech, Little Chalfont, England), and immunoblotted with an mAb specific for T202/Y204 doubly-phosphorylated p44/42 MAPK (Cell Signaling Technology Inc., Beverly, Massachusetts, USA). Blots were then stripped and reprobed with a polyclonal Ab recognizing p42 MAPK (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA). Survivin immunoblotting was performed as previously described (14) . For proteins related to cell cycle and apoptosis, the following primary Ab's were used: anti-phospho-p27 Kip1 (T187) rabbit polyclonal Ab (Zymed Laboratories Inc., San Francisco, California, USA), anti-p27 Kip1 mAb, anti-Mcl-1 mAb (both from PharMingen, San Diego, California, USA), anti-Waf-1 mAb, anti-Bcl-X L mAb (both from Oncogene Research Products, Cambridge, Massachusetts, USA), and anti-Bcl-2 mAb (DAKO Corp., Carpinteria, California, USA). MAPK enzymatic activity was assessed by immunoprecipitation and in vitro kinase assay using the p44/42 MAP Kinase Assay Kit (Cell Signaling Technology Inc.).
Quantitative real-time RT-PCR. OCI-AML3 cells were treated with either DMSO or PD98059, and RNA was isolated with TRIzol solution (Life Technologies Inc., Grand Island, New York, USA). One microgram of total RNA was reverse transcribed by AMV reverse transcriptase (Roche Diagnostic Corp.) at 42°C for 1 hour. PCR amplification reaction mixtures (25 µl) contained cDNA, p21 Waf1/CIP1 (5′-CGCTAATGGCGGGCTG-3′) or p27 Kip1 (5′-GAGGACACGCATTTGGTGG-3′) forward primers, p21 Waf1/CIP1 (5′-CGGTGACAAAGTCGAAGTTCC-3′) or p27 Kip1 (5′-GCTCCGCTAACCCCGTCT-3′) reverse primers, p21 Waf1/CIP1 (5′-ATCCAGGAGGCCCGTGAGCGA-3′) or p27 Kip1 (5′-CCCAAAGACTGATCCGTCGGACAGC-3′) probes, and TaqMan Universal PCR Master Mix (PE Applied Biosystems, Foster City, California, USA). β 2 -microglobulin (β 2 -m) coamplified with p21 Waf1/CIP1 and p27 Kip1 was included as internal control for normalization of the variable content of cDNA in each sample (forward primer 5′-AGCTGTGCTCGCGCTACTCT-3′, reverse primer 5′-TTGACTTTCCATTCTCTGCTGG-3′, probe 5′-TCTTTCTGGCCTGGAGGGCATCC-3′). Thermal cycle conditions included holding the reactions at 50°C for 2 minutes and at 95°C for 10 minutes, and cycling for 40 cycles between 95°C for 15 seconds and 60°C for 1 minute. Results were collected and analyzed with an ABI Prism 7700 Sequence Detection System (PE Applied Biosystems) as follows: the PCR cycle number that generated the first fluorescence signal above a threshold (threshold cycle, C T ; 10 SDs above the mean fluorescence generated during the baseline cycles) was determined, and a comparative C T method was then used to measure relative gene expression. The following formula was used to calculate the relative amount of the transcript of interest in the treated sample (X) and the control sample (Y), both normalized to an endogenous reference (β 2 -m): 2 -∆∆CT , where ∆C T is the difference in C T between the gene of interest and β 2 -m, and ∆∆C T for sample X = ∆C T (X) -∆C T (Y). ulated in most AML patients (S.M. Kornblau, unpublished observations). We therefore investigated the functional consequences of the pharmacological disruption of the MEK/MAPK module using the selective inhibitor of MEK activation PD98059. Among the AML cell lines tested, OCI-AML3, HL-60, and NB4 showed high steadystate levels of doubly phosphorylated (i.e., active) MAPK (Figure 1a) . MAPK activation appeared to be constitutive in that comparably high levels of MAPK phosphorylation were detectable even after 48 hours of serum starvation (data not shown). As shown in Figure 1 , b and c, PD98059 inhibited MAPK phosphorylation and enzymatic activity downstream of MEK in OCI-AML3 cells in a dose-dependent manner. MEK blockade resulted in a profound, dose-dependent growth inhibition in OCI-AML3 and HL-60 cells, and a less extensive inhibition in NB4 cells (Table 1) . Conversely, U937 and KG1 cells, which showed low levels of constitutive MAPK activation (Figure 1a) , proved relatively resistant (Table 1) .
In primary AML samples, PD98059 (20 µM) caused a greater than 25% decrease in the recovery of viable cells after short-term in vitro culture in 14 of 19 samples tested (median reduction in sensitive samples, 40%; range, 26-60%) ( Table 2) . MEK blockade by PD98059 profoundly affected primary AML cell growth and viability at the progenitor cell level, as shown by the striking dosedependent decrease in the number of AML blast colonies observed in all four samples tested (Figure 1d ). Conversely, no reduction in either cell viability or clonogenic potential was observed in response to MEK blockade in CD34-selected progenitors (n = 4) and bone marrow cells (n = 2) from healthy donors (Figure 1e ).
Collectively, these findings indicate that disruption of the MEK/MAPK module selectively inhibits the growth of AML cell lines and primary samples, but not that of normal hematopoietic progenitors.
MEK blockade inhibits cell cycle progression. Consistent with the observed inhibition of cell growth, PD98059 caused a dose-and time-dependent inhibition of G 1 /S transition, with accumulation of cells in the G 1 phase in MEK inhibition-sensitive cell lines and primary samples ( Figure 2 , a and d). Conversely, the resistant cell lines U937 and KG1 showed a slight inhibition of cell cycle progression only at the highest dose (data not shown). Western blot analysis showed that MEK inhibition-induced cell cycle arrest was accompanied by downregulation of p21 Waf1/CIP1 and upregulation of p27 Kip1 in sensitive cell lines (OCI-AML3 and HL-60), but not in resistant cell lines (U937) (Figure 2b ). Levels of p21 Waf1/CIP1 RNA decreased strikingly in response to PD98059 in a timedependent fashion (Figure 2c ), suggesting the possibility of direct transcriptional regulation (19) . Conversely, p27 Kip1 RNA levels remained relatively constant following exposure to PD98059. However, T187 phosphorylation, a posttranslational modification that targets p27 Kip1 for proteasome-mediated degradation (20) , was already decreased by PD98059 after 2 hours, suggesting that protein stabilization occurs before changes in cell cycle distribution are detectable (Figure 2d) .
MEK inhibition induces apoptosis in AML cell lines and primary AML samples. Consistent with the reported reversibility of MEK inhibition, removal of PD98059 from the culture medium promptly restored cell cycle progression and growth in HL-60 and NB4 cells (data not shown). By contrast, OCI-AML3 cells showed sustained growth impairment even 96 hours after PD98059 removal (data not shown). Since the MEK/MAPK pathway is considered a key regulator of apoptotic cell death (21, 22) , we tested the hypothesis that sustained growth impairment might be due to induction of apoptosis. Treatment of OCI-AML3 cells with 20 µM PD98059 caused a time-dependent increase in the percentage of annexin V-binding cells that was detectable within 48 hours, and reached maximum levels after 96 hours (Figure 3a) . Phosphatidylserine exposure on the outer leaflet of the plasma membrane was accompanied by caspase-3 activation and a decrease in the DNA content to hypodiploid levels (data not shown). A slight increase in apoptosis was also induced by PD98059 in HL-60 cells, but not in the other cell lines tested (data not shown). A net increase in the proportion of apoptotic cells of more than 10%, as detected by annexin V binding and hypodiploid DNA content, was observed in 11 of 18 primary AML samples after exposure to 20 µM PD98059 (median net apoptosis increase in sensitive samples, 13%; range, 10-23%; data not shown). The dose dependency of PD98059-induced apoptosis in MEK inhibition-sen- sitive samples (n = 3) is shown in Figure 3b . Conversely, no induction of apoptosis, but rather a slight protection from spontaneous cell death in cytokine-free cultures, was observed in normal CD34 + progenitor cells from healthy donors following treatment with PD98059 (20 µM; n = 4) (data not shown). MEK inhibition sensitizes AML cells to retinoid-and chemotherapy-induced apoptosis. PD98059 (20 µM) also potently sensitized AML cell lines with constitutive MAPK activation (OCI-AML3, NB4, HL-60), but not those with low steady-state levels of MAPK activity (U937, KG1), to ATRA-induced apoptosis (Figure 3c ). Apoptosis was not caused by increased differentiation; on the contrary, ATRA-induced differentiation was partially blocked by simultaneous MEK inhibition, as previously reported (23) . A similar degree of sensitization was observed in response to the pan-RA receptor agonist 9-cis-RA, but not to RAR-or RXR-selective ligands, suggesting that this proapoptotic effect requires simultaneous activation of both the RAR and RXR pathways (data not shown). Moreover, when HL-60 cells were exposed to clinically relevant concentrations (10 µM) of Ara-C for short periods (4 hours), the subsequent exposure to PD98059 (20 µM) greatly potentiated drug-induced apoptosis (Figure 3d) , and completely prevented regrowth of the leukemic cells for up to 9 days. This effect was strictly sequence dependent, in that pretreatment with PD98059 did not sensitize leukemic cells to, but rather slightly protected them from Ara-C-induced killing (data not shown). Similar results were obtained in OCI-AML3 and NB4 cells, whereas no such effect was observed in U937 and KG1 cells (data not shown).
MEK inhibition downregulates antiapoptotic proteins of the "inhibitor of apoptosis protein" and Bcl-2 families.
In an attempt to elucidate the molecular mechanisms underlying the lowering of the apoptotic threshold in response to MEK blockade, we examined whether PD98059 affected the expression of antiapoptotic proteins of the "inhibitor of apoptosis protein" (IAP) and Bcl-2 families. We have recently reported that survivin expression is regulated through MAPK-dependent mechanisms in OCI-AML3 cells (14) . Here we show that survivin levels were significantly decreased by treatment with 20 µM PD98059 in the MEK inhibition-sensitive cell lines (OCI-AML3 and HL-60), but not in the resistant cell lines (U937; Figure 4a ). Overall, a strong, statis- tically significant correlation was observed between constitutive MAPK activation and the reduction in survivin levels in response to MEK inhibition (R 2 = 0.9104, P = 0.012; Figure 4b ). Antiapoptotic protein XIAP levels were only slightly affected. PD98059 also significantly decreased Mcl-1 expression, whereas no changes in Bcl-2 and Bcl-X L levels were detected, with the notable exception of HL-60 cells, in which Bcl-X L became undetectable within 48 hours (Figure 4a) .
Effects of the novel MEK inhibitor PD184352 in AML cell lines and primary samples. Sebolt-Leopold et al. have recently
reported that the novel, orally bioavailable MEK inhibitor PD184352 successfully suppresses the growth of colon tumors in vivo without causing overt toxicity (17) . We therefore tested its effects in AML cell lines and primary AML samples. Consistent with results reported in different cellular models (17, 24) , PD184352 inhibited MAPK phosphorylation and cell growth at nanomolar concentrations in sensitive cell lines ( Figure 5 , a and b; Table 1 ). In primary AML samples, PD184352 (10 µM) caused a greater than 25% decrease in the recovery of viable cells in seven of nine samples tested (median, 54%; range, 36--57%; Table 2 ). The pattern of sensitivity to the growthinhibiting effects of PD184352 was superimposable on that observed with PD98059 in primary samples tested for response to both MEK inhibitors (n = 5; Table 2 and data not shown). PD184352 caused G 1 arrest (Figure 5c ), and at higher doses (1-10 µM), induced apoptotic cell death in cells with constitutive MAPK activation (OCI-AML3, HL-60, NB4), but not in those with low steadystate levels of MAPK activity (U937, KG1) (Figure 5b and data not shown). A net increase of more than 10% in the proportion of apoptotic cells was also observed in seven of nine primary AML samples (median, 17%; range 11-72%) after exposure to 10 µM PD184352 (data not shown). In contrast, no reduction in cell viability or increase in apoptosis was observed in normal CD34 + progenitor cells from healthy donors (n = 3) following exposure to 10 µM PD184352 (data not shown).
Interestingly, a strong, statistically significant correlation between steady-state levels of active MAPK and sensitivity to the growth-inhibiting effect of
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The PD184352 was observed in AML cell lines (R 2 = 0.8933, P = 0.015; Figure 5d ). Likewise, MEK inhibition-sensitive primary AML samples (n = 4) showed high levels of constitutive MAPK phosphorylation, whereas MAPK phosphorylation was barely detectable in resistant samples (n = 3, P = 0.01) and in normal CD34 + progenitors (Figure 5e ).
Discussion
Here we provide evidence that small-molecule inhibitors of the MEK/MAPK pathway profoundly affect the growth of AML cell lines and primary AML samples with constitutive MAPK activation, but have little effect on cells with low steady-state MAPK activity. Cell growth was inhibited as a result of cell cycle arrest and induction of apoptosis, and resulted in the abrogation of leukemic, but not normal, hematopoietic cell clonogenicity. In addition, MEK inhibition profoundly sensitized leukemic cells to the proapoptotic effects of retinoids and chemotherapy. Consistent with the proposed role of the RAS/MAPK pathway in the regulation of G 1 /S transition (25), both MEK inhibitors caused cell cycle arrest in sensitive AML cell lines and primary samples. Constitutive activation of the MEK/MAPK pathway results in decreased expression of the cyclin-dependent kinase inhibitor p27 Kip1 in different cell types, and recent data show that MAPK regulates p27 Kip1 turnover at a posttranslational level (26, 27) . Our data demonstrate that, in AML cell lines with constitutive MAPK activation, p27 Kip1 turnover is similarly regulated through MAPK-dependent mechanisms. Likewise, the observed decrease in p21 Waf1/CIP1 levels in response to MEK inhibition is consistent with the reported ability of MAPK to transcriptionally induce p21 Waf1/CIP1 expression (19) . While downregulation of p21 Waf1/CIP1 argues against its involvement in the observed inhibition of cell cycle progression, decreased levels of expression may play a role in the MEK inhibition-induced sensitization to the proapoptotic effects of retinoids and chemotherapy (28, 29) . The potential clinical relevance of these findings is highlighted by recent reports that both low levels of p27 Kip1 and high levels of p21 Waf1/CIP1 confer a poor clinical outcome to AML patients (30, 31) .
The evidence presented here suggests that MEK blockade alters the apoptotic balance by reducing the expression of both upstream (Mcl-1, Bcl-X L ) and downstream (survivin) antiapoptotic proteins in cells that rely heavily on MAPK activation for their growth and survival. Although the relative importance of each of these players in the MEK inhibition-mediated lowering of the apoptotic threshold deserves further investigation, changes in survivin expression show the best correlation with the functional response to disruption of the MEK/MAPK module. These findings are consistent with recent observations showing that the MEK/MAPK pathway protects against apoptosis at the level of cytosolic caspase activation, without interfering with the release of cytochrome c from mitochondria, strongly suggesting the involvement of an IAP-like molecule (32) . Despite the above-described molecular changes, MEK inhibitors, at doses close to the IC 50 for MAPK enzymatic activity, have cytostatic rather than cytotoxic effects, and higher doses are required to trigger apoptosis. However, MEK blockade sets the stage for increased sensitivity to other apoptotic stimuli, such as retinoids and DNA-damaging agents. Although MAPK may regulate Bcl-2 antiapoptotic activity at a posttranslational level (33), we show here that MEK inhibition does not affect its protein expression; therefore, in the absence of additional cellular stresses, above-threshold levels of Bcl-2 can maintain cell viability even in the presence of low levels of other antiapoptotic players (such as Mcl-1 and survivin). This might in turn explain the proapoptotic synergism observed for the combination of ATRA treatment and Based on its ability to lower the apoptotic threshold, disruption of the MEK/MAPK module has been proposed as a novel approach to the chemosensitization of cancer cells (36) . Although our findings support this concept, they differ from previously reported results in two clinically relevant aspects. First, we found that only cell lines with constitutive activation of the MAPK pathway were sensitized to Ara-C-induced apoptosis, suggesting that the observed effect may depend on intrinsic rather than Ara-C-stimulated MAPK activity, as previously suggested (37) . Second, as recently reported for paclitaxel (38) , the Ara-C-potentiating effect was strictly sequence dependent. Ara-C followed by PD98059 substantially potentiated Ara-C-induced apoptosis, completely abrogating the ability of leukemic cells to recover from the cytotoxic insult, whereas the reverse sequence had a slight protective effect. The reduced efficacy of the combination of PD98059 followed by Ara-C may be related to the inhibition of cell cycle progression, which would result in decreased incorporation of Ara-C, and has potential implications for the design of clinical trials using MEKtargeted therapies as chemosensitizers.
The usefulness of mechanism-targeted therapeutic strategies, such as MEK inhibition, will ultimately depend on the ability to prospectively select those patients most likely to benefit from a specific intervention. Recent studies have shown that constitutive deregulation of specific pathways is the mechanism responsible for the sensitivity of cancer cells to signal-transduction inhibitors (39) (40) (41) . In agreement with recent findings in different tumor models (17, 42) , we observed a significant correlation between constitutive MAPK phosphorylation and sensitivity to MEK blockade-induced growth inhibition in both AML cell lines and primary AML samples. Along these lines, the lack of constitutive MAPK activation in normal hematopoietic progenitors (ref. 10 and Figure 5e ) may explain their relative resistance to MEK inhibition, as observed here and in other recently published studies (43, 44) , providing the basis for a selective antileukemic effect.
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